Responders exhibit a dominant signature characterized by IL1B, MIF, CXCL5, and HMGB1—indicating an inflamed, neutrophil-rich tumor microenvironment (TME) that is primed for antitumor immunity. The gene discussed is CXCL5; the disease is neoplasm.